LIVE RECOMBINANT CANARY POX ALVAC HIV VCP 300 IN HIV UNINFECTED VOLUNTEERS

活体重组金丝雀痘 ALVAC HIV VCP 300 用于未感染 HIV 的志愿者

• 批准号: 6115597
• 负责人: BARNEY S GRAHAM
• 金额: $ 3.64万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6115597
• 关键词: AIDS therapy; AIDS vaccines; HIV envelope protein; HIV envelope protein gp120; HIV envelope protein gp41; HIV infections; clinical research; clinical trial phase I; cytotoxic T lymphocyte; drug screening /evaluation; gag protein; human subject; human therapy evaluation; recombinant virus; vector vaccine

To evaluate the safety and immunogenicity of ALVAC-MN120TMGNP v CP300, a recombinant canarypox vector into which the following genes have been inserted: HIV-1 envelope gp120 (strain MN) linked to the transmembrane portion of HIV-1 gp41 (Strain LAI) and the HIV-1 genes encoding the entire gag protein (LAI); a portion of the pol sequence sufficent to evoke protease (LAI); three pol peptides containing CTL epitopes (LAI); and two peptides in the nef (MN) gene containing CTL epitopes. Our focus is on continuing recruitment and volunteer follow up.

为了评价ALVAC-MN 120 TMGNP v CP 300的安全性和免疫原性， 一种重组金丝雀痘病毒载体， 插入：HIV-1包膜gp 120（MN株）连接至跨膜 HIV-1 gp 41部分（LAI株）和编码HIV-1 gp 41的HIV-1基因 完整的gag蛋白（LAI）; pol序列的一部分，足以 诱发蛋白酶（LAI）;含CTL表位的三聚肽（LAI）; 和nef（MN）基因中的两个含有CTL表位的肽。 我们的重点是继续招募和志愿者跟进。